Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial

作者：Juergen Rockstroh, Sheetal Kassim, Roger Paredes, Christopher Bettacchi, Gary I Sinclair, Anchalee Avihingsanon, Nelly Mugo, Jean-Michel Molina, Brenda Crabtree Ramírez, Hiroyuki Gatanaga, Yayun Xu, Stephanie O. Klopfer, Tracy L. Diamond, Mary Vesnesky, Luisa M. Stamm, Michelle C Fox, Mary L. Pisculli · 发表于：The Lancet HIV · 年份：2026 · DOI：10.1016/s2352-3018(26)00033-0 · 被引用次数：9 · 研究领域：HIV/AIDS drug development and treatment、HIV-related health complications and treatments、HIV/AIDS Research and Interventions